肺動(dòng)脈高壓是一類以肺血管阻力進(jìn)行性升高為主要特征的疾病，致殘率和病死率都很高。由于多種疾病均可導(dǎo)致肺動(dòng)脈高壓的發(fā)生，因此其機(jī)制研究發(fā)展迅速，也出現(xiàn)了針對肺高壓多種發(fā)病機(jī)制及其不同環(huán)節(jié)而研發(fā)的新型靶向藥。綜述目前與肺動(dòng)脈高壓發(fā)病機(jī)制相關(guān)的新型生物標(biāo)志物，并將其按照功能進(jìn)行分類，包括內(nèi)皮細(xì)胞功能失調(diào)、炎癥、表觀遺傳學(xué)、心臟功能、氧化應(yīng)激、細(xì)胞外基質(zhì)等內(nèi)容，為該病的臨床早期診斷、疾病分型、嚴(yán)重程度判斷等提供有效依據(jù)，進(jìn)而為精準(zhǔn)治療以及新藥研發(fā)提供依據(jù)。

Pulmonary arterial hypertension is characterized by elevated pulmonary arterial pressure with high disabled rate and lethality. Since many causes could lead to pulmonary arterial hypertension, the mechanism studies were developed rapidly, and some new therapeutic targets have been explored according to the multiple pathogenic mechanisms and pathways. We summarized the potential and novel biomarkers of the mechanisms associated with pulmonary arterial hypertension, and categorized based on their relationship to endothelial cell dysfunction, inflammation, epigenetics, cardiac function, oxidative stress, extracellular matrix, etc. The biomarkers can help for diagnosis, sorting, disease severity assessment of PAH, in order to provide the basis for precision treatment and new therapeutic target development.

國家自然科學(xué)基金（81672073，81301485）；天津市衛(wèi)計(jì)委科技基金（2015KY34）